The Goldman Sachs Group Cuts Humana (NYSE:HUM) Price Target to $158.00

Humana (NYSE:HUM) had its target price cut by The Goldman Sachs Group from $215.00 to $158.00 in a research note released on Friday morning,MarketScreener reports. They currently have a sell rating on the insurance provider’s stock.

Several other research firms have also issued reports on HUM. JPMorgan Chase & Co. lowered their price target on shares of Humana from $274.00 to $180.00 and set a “neutral” rating on the stock in a research report on Friday. Guggenheim decreased their price target on Humana from $312.00 to $252.00 and set a “buy” rating on the stock in a research note on Thursday. UBS Group cut their price target on shares of Humana from $285.00 to $195.00 and set a “neutral” rating on the stock in a report on Thursday. Robert W. Baird cut their price objective on shares of Humana from $280.00 to $264.00 and set a “neutral” rating on the stock in a report on Thursday, December 11th. Finally, Royal Bank Of Canada downgraded shares of Humana from an “outperform” rating to a “sector perform” rating and reduced their price target for the company from $322.00 to $189.00 in a research report on Thursday. Seven research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and five have assigned a Sell rating to the company. According to data from MarketBeat.com, Humana presently has an average rating of “Hold” and a consensus price target of $238.29.

Humana Stock Performance

Shares of Humana stock opened at $183.92 on Friday. The firm has a market capitalization of $22.12 billion, a price-to-earnings ratio of 18.73, a PEG ratio of 1.96 and a beta of 0.44. The business has a 50-day simple moving average of $244.65 and a 200 day simple moving average of $261.02. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.00 and a quick ratio of 2.02. Humana has a one year low of $169.61 and a one year high of $315.35.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.01) by $0.05. Humana had a return on equity of 11.43% and a net margin of 0.92%.The business had revenue of $32.64 billion during the quarter, compared to the consensus estimate of $32.08 billion. During the same quarter in the previous year, the business earned ($2.16) EPS. The company’s quarterly revenue was up 11.3% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. On average, research analysts anticipate that Humana will post 16.47 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Humana

Several institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in shares of Humana by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 14,261,860 shares of the insurance provider’s stock valued at $3,652,890,000 after buying an additional 106,030 shares in the last quarter. Dodge & Cox lifted its holdings in shares of Humana by 5.6% in the 2nd quarter. Dodge & Cox now owns 11,352,920 shares of the insurance provider’s stock worth $2,775,562,000 after purchasing an additional 597,705 shares during the last quarter. Capital International Investors boosted its stake in Humana by 113.9% during the 4th quarter. Capital International Investors now owns 5,818,008 shares of the insurance provider’s stock valued at $1,490,239,000 after purchasing an additional 3,097,571 shares during the period. State Street Corp raised its stake in shares of Humana by 1.8% during the fourth quarter. State Street Corp now owns 5,462,549 shares of the insurance provider’s stock valued at $1,403,877,000 after purchasing an additional 97,211 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its holdings in shares of Humana by 28.9% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,496,775 shares of the insurance provider’s stock valued at $1,151,759,000 after acquiring an additional 1,008,514 shares in the last quarter. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Key Humana News

Here are the key news stories impacting Humana this week:

• Positive Sentiment: CenterWell (Humana’s healthcare services unit) closed the acquisition of MaxHealth, adding a sizable Florida primary‑care network (~82 owned/affiliated clinics and >80,000 patients in value‑based programs) which expands Humana’s senior-focused, value‑based primary care footprint and accelerates revenue and membership growth in higher-value care. CenterWell Completes Acquisition of MaxHealth
• Positive Sentiment: Management signals more primary‑care deals may be coming (CEO remarks and media reports about a potential ~$1B strategic push), reinforcing the company’s strategy to grow value‑based care capacity — a long‑term growth catalyst if Humana can scale clinics and convert MA members to higher‑margin care. Humana CEO hints at upcoming primary care deal
• Neutral Sentiment: Jefferies cut its price target (from $310 to $235) but kept a Buy rating, reflecting disagreement among analysts on Humana’s growth vs. margin tradeoff — some firms still see upside despite lower near‑term earnings visibility. Jefferies price target change
• Negative Sentiment: Several major analysts materially lowered price targets and trimmed estimates (TD Cowen to $173 Hold; JPMorgan to $180 Neutral; Evercore, Cantor, Leerink also cut targets), reflecting concern that Medicare Advantage cost pressures, lower quality (STAR) ratings, and a cautious 2026 earnings guide will weigh on near‑term profitability. TD Cowen PT cut
• Negative Sentiment: Humana reported a fourth‑quarter loss and issued a cautious 2026 outlook (management flagged sharply lower near‑term earnings as Medicare Advantage membership surges but margins remain under pressure), which prompted analysts to slash forecasts and is the primary fundamental reason for downward pressure on the stock. Humana stock falls on disappointing earnings forecast

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.